Pulling SEC filings + quote and writing the call…

MeiraGTx Holdings plc
Next earnings Aug 12, 2026 · consensus $-0.42 EPS, $16.0M rev
Last earnings -0.2% on 2026-05-14
Clinical-stage gene-therapy story with negative equity, deepening current-liability crunch and only ~6 months of cash — too fragile at 11.7x sales.
MeiraGTx is a clinical-stage genetic medicines company that, by its own admission in the 10-K, 'has not generated any product revenues to date' and does 'not expect to generate revenue from sales of products unless and until we successfully initiate and complete clinical development and obtain regulatory approval.' The FY2025 'revenue' of $81.4M is therefore not product sales but collaboration/milestone recognition (J&J $130M collab + $125M asset purchase, plus $75M Lilly and $50M Hologen contributions disclosed in the MD&A). That makes the headline +144.6% YoY growth and 11.7x P/S misleading as a fundamentals signal — it is lumpy partner cash, not a recurring commercial run-rate.
Sources: SEC EDGAR (CIK 0001735438, latest 10-Q filed 2026-05-14) · EODHD · analysis by claude-code · as of 6/25/2026, 2:12:53 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $14.0M | $33.3M | $81.4M |
| Gross profit | — | — | — | — | — |
| Operating income | -$72.8M | -$116M | -$137M | -$164M | -$106M |
| Net income | -$79.6M | -$130M | -$84.0M | -$148M | -$114M |
| Diluted EPS | -$1.80 | -$2.87 | -$1.49 | -$2.12 | -$1.42 |
| Net margin | — | — | -599.5% | -444.1% | -140.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting vote results disclosed; routine governance items approved
Q1 2026 10-Q: collab revenue scaling but operating losses and cash burn continue
Q1 2026 10-Q: collab revenue scaling but operating losses and cash burn continue
2026 proxy: director slate and compensation items put to shareholder vote
Entered new material definitive agreement; pipeline/financing terms filed
Reg FD/corporate update accompanying J&J transaction disclosures
Reg FD/corporate update accompanying J&J transaction disclosures
Reg FD/corporate update accompanying J&J transaction disclosures
FY25: revenue $81M (+145%) on J&J/Lilly deals; loss narrowed to $114M
1047 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-06-10 | Harris Keith R. Director | Exercise | 75.0K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.